机构投资者增加了Eli Lilly的股份,尽管收入估计数缺失。 Institutional investors boost stakes in Eli Lilly, despite missing earnings estimates.

Chelsea顾问公司和Armis顾问有限公司等机构投资者在Eli Lilly和一家制药公司(Corporation,一家制药公司)的股权日益增加。 Institutional investors like Chelsea Counsel Co. and Armis Advisers LLC are increasing their stakes in Eli Lilly and Company, a pharmaceutical firm. 切尔西律师公司将其股份提高了7%,Armis顾问有限公司购买了755股股票。 Chelsea Counsel Co. raised its holdings by 7%, and Armis Advisers LLC bought 755 shares. 尽管Eli Lilly失踪了收入估计数,分析师还是持肯定态度,评级为“Moderate Buy”,价格目标为1 011.37美元。 Despite Eli Lilly missing earnings estimates, analysts are positive, with a "Moderate Buy" rating and a price target of $1,011.37. 该公司的收入逐年增长45.2%。 The company's revenue grew 45.2% year-over-year.